Revenue

Glucotrack seeks FDA trial approval for its revolutionary 3-year implantable glucose monitor, racing against financial clocks to change diabetes care.

Amid major Medicare policy shifts, Nuo Therapeutics reports a 169% revenue surge, positioning its Aurix wound care system as a key market disruptor.

A new study finds a minimally invasive procedure provides greater short-term weight loss than a popular pill, reshaping the debate on obesity treatment.

The iconic American rib chain is back in China, but this is more than just a restaurant opening. It's a high-tech, high-stakes bet on the future.

Nubank's AI-first strategy drives record revenue and profitability in Mexico, but rising delinquencies test its advanced risk management models.

A Houston firm is set to make waves with a rare Modigliani drawing and a private Dalí painting, complete with personal letters from the artist.

As its CFO presents at a top NYC conference, Healios K.K. advances novel stem cell treatments for ARDS, stroke, and cancer into critical global trials.

Westaim posted a $33.4M Q1 loss, but strong early sales from its new annuity product suggest a long-term strategic transformation is taking root.

The Solana treasury firm reported a massive GAAP loss due to SOL's price drop, but it also secured new debt, bought back shares, and pushed into new markets.

Out of 600+ plans, Alignment Health is one of just four to earn a top award for medication quality. Here's what that means for seniors and the industry.

Figma's revenue growth accelerated to 46% in Q1, driven by the successful monetization of its AI tools and deepening enterprise adoption.

Boston Omaha posts higher revenue and operational cash flow, but a wider net loss driven by investment headwinds reveals a complex picture for investors.

Edesa Biotech pushes its pipeline forward with a new vitiligo trial and promising ARDS data, but rising R&D costs highlight the high stakes of innovation.

The chip equipment giant posts record Q2 revenue and profit, driven by surging AI demand, and unveils major partnerships to accelerate future tech.

The biotech firm is set to launch its first commercial products, using an innovative strategy to tackle long-neglected markets in women's healthcare.

From the NFL to the NCAA, Robert Turbin's Belen Creative partners with major universities to redefine school spirit through strategic, high-impact merchandise.

Amid cannabis market woes, SpringBig slashes costs to reach positive Adjusted EBITDA. Can its AI platform and a bold push into gaming save the company?

The former Novant Health exec and investment banker helped build the collaborative; now he’s tasked with guiding its financial strategy and expansion.

With five years of record revenue, all eyes are on Build-A-Bear's upcoming Q1 results to see if its 'retailtainment' model can defy market headwinds.

After a decade-long legal battle, minority shareholders of e-commerce firm Dangdang secured a $21M settlement over an allegedly unfair merger.